Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Artivion (AORT)
NYSE:AORT
Holding AORT?
Track your performance easily
Earnings Data
Report Date
Feb 13, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.07Last Year’s EPS
-$0.1Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: -1.73%
|Next Earnings Date:Feb 13, 2025
Earnings Call Sentiment|Positive
The call reflects a positive outlook with strong financial performance and significant advancements in regulatory and clinical areas. While there are minor challenges in tissue processing and PerClot revenue, the overall growth strategy and product performance remain robust.Company Guidance
In the third quarter of 2024, Artivion reported strong financial performance, achieving a 10% year-over-year constant currency revenue growth to $95.8 million and a 28% increase in adjusted EBITDA compared to Q3 2023. The company's product portfolio showed significant growth, with On-X revenues up 15%, BioGlue growing 14%, and stent graft revenues increasing 13% year-over-year. Geographically, Latin America and Asia Pacific saw remarkable revenue growth of 32% and 23%, respectively. The company also made progress with regulatory approvals, including filing the first PMA module for AMDS with the FDA and receiving approval to commercialize BioGlue in China, expected to begin in the second half of 2025. Despite a slight decline in tissue processing growth due to donor allograft volume fluctuations, overall performance was robust, positioning the company well for sustained double-digit revenue growth and EBITDA margin expansion.Strong Revenue and EBITDA Growth
Delivered constant currency revenue growth of 10% year-over-year, reaching $95.8 million in revenue. Adjusted EBITDA grew 28% year-over-year, with a margin improvement of 270 basis points.
Product Performance Highlights
On-X revenues increased 15%, BioGlue grew 14%, and stent graft revenues grew 13% on a constant currency basis year-over-year. Tissue processing revenues grew 2% despite donor allograft volume challenges.
Geographic Growth
Strong revenue growth in Latin America and Asia Pacific, with 32% and 23% constant currency growth, respectively.
Regulatory and Clinical Advances
Filed the first module of the PMA application for AMDS with the FDA. Received regulatory approval for BioGlue in China and completed enrollment in the TRIOMPHE trial for NEXUS.
Positive Clinical Trial Results
AMDS showed 94% of patients were free from aortic reoperation in the DART trial. Persevere trial showed a cerebral malperfusion resolution of 90% of affected subjects.
---
AORT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AORT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $28.98 | $28.71 | -0.93% |
| Aug 08, 2024 | $25.33 | $24.85 | -1.89% |
| May 06, 2024 | $21.07 | $23.77 | +12.81% |
| Feb 15, 2024 | $18.04 | $18.81 | +4.27% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Artivion (AORT) report earnings?
Artivion (AORT) is schdueled to report earning on Feb 13, 2025, TBA Not Confirmed.
What is Artivion (AORT) earnings time?
Artivion (AORT) earnings time is at Feb 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AORT EPS forecast?
AORT EPS forecast for the fiscal quarter 2024 (Q4) is -$0.07.
---